US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&P 500 Gain For Third Year In A Row, But Says 'Investors Should Be Optimistic'
Market Overview: U.S. stock futures showed little movement after a recent rally, with investors reacting to President Trump's tariff announcements that may not take effect immediately, while the Federal Reserve is expected to maintain interest rates unchanged for March.
Stock Performance Highlights: Major indices saw gains on Thursday, led by sectors like materials and technology; notable individual stock movements included Airbnb's significant rise post-earnings and declines for Mynaric AG following a delisting notification.
Trade with 70% Backtested Accuracy
Analyst Views on MBRX
About MBRX
About the author
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
- Clinical Trial Progress: Moleculin expects to complete the unblinding of data for 45 subjects in the MIRACLE trial in Q1 2026, which is anticipated to provide critical efficacy data for treating acute myeloid leukemia (AML), thereby enhancing Annamycin's market recognition.
- New Indication Expansion: Annamycin is set to initiate a clinical trial for pancreatic cancer in 2026, funded by Atlantic Health, based on preclinical data showing unexpected activity in pancreatic cancer models, further enhancing its market potential.
- Global Trial Network: The MIRACLE trial has expanded to nine countries, including the US and several European nations, with 46 trial sites selected, and is expected to recruit the 90th subject by Q1 2026, demonstrating the company's strong execution capabilities on a global scale.
- Significant Market Opportunity: Annamycin is poised to become the world's first non-cardiotoxic anthracycline, and given that nearly half of cancer patients currently use cardiotoxic drugs, the market demand potential is enormous, likely attracting increased investor interest.
Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors
Stock Performance: Moleculin Biotech, Inc. (MBRX) shares fell 16.84% to $3.90 despite reporting positive results from a Phase 1 clinical trial of WP1066 for children with recurrent malignant brain tumors.
Clinical Trial Results: The trial indicated that the treatment was safe, induced anti-tumor immune responses, and suppressed STAT3 activity, showing promising signs in a challenging pediatric cancer context.
Market Reaction: Following the announcement, the stock experienced significant volatility and a steep sell-off, with trading activity exceeding average levels as investors reassessed the company's near-term risks.
Trading Range: MBRX's stock trades within a 52-week range of approximately $3.63 to $91.25, highlighting its volatility in the biotech market.
